Proton Radiotherapy Alone versus Combined with Immunotherapies or Tyrosine Kinase Inhibitors for Barcelona Clinic Liver Cancer Stage B or C Hepatocellular Carcinoma
Authors:
- Rodney Cheng-En HsiehRHRodney Cheng-En Hsieh
- Willy Po-Yuan ChenWCWilly Po-Yuan Chen
- Jin-Chiao LeeJLJin-Chiao Lee
- Chia-Hsin LinCLChia-Hsin Lin
- Yu-Chen ChangYCYu-Chen Chang
- Chao-Wei LeeCLChao-Wei Lee
- Kun-Ming ChanKCKun-Ming Chan
- Hao-Chien HungHHHao-Chien Hung
- Tony KuoTKTony Kuo
- Shen-Yen LinSLShen-Yen Lin
- Tse-Ching ChenTCTse-Ching Chen
- Ting-Jung WuTWTing-Jung Wu
Open Access
- 12 December 2025
- journal article
- Published by S. Karger AG in Liver Cancer
- p. 1-16
Abstract
Purpose: This study aimed to compare the outcomes of proton radiotherapy alone versus its combination with immuno-oncology agents (Proton-IO) or tyrosine kinase inhibitors (Proton-TKI) in patients with intermediate- to advanced-stage hepatocellular carcinoma (HCC). Methods: We retrospectively reviewed the medical records of 137 patients with Barcelona Clinic Liver Cancer (BCLC) stage B or C HCC treated with proton radiotherapy at Linkou Chang Gung Memorial Hospital between 2020 and 2023. Patients were stratified into three groups: proton radiotherapy alone (n = 64), Proton-IO (n = 44), and Proton-TKI (n = 29). The most frequently used immuno-oncology agents were atezolizumab-bevacizumab (n = 33) and pembrolizumab (n = 5). Tyrosine kinase inhibitors (TKIs) included lenvatinib (n = 16) and sorafenib (n = 13). Results: With a median follow-up of 30 months, patients in the Proton-IO group were significantly associated with higher 2-year overall survival (OS) rates compared with those receiving Proton-TKI or proton radiotherapy alone (77.0% vs. 47.2% vs. 52.7%; p = 0.002). Proton-IO was also associated with significantly longer time to progression (TTP) and distant metastasis-free survival (DMFS) (2-year TTP: 50.5% vs. 28.1% vs. 24.2%, p = 0.003; 2-year DMFS: 83.4% vs. 61.1% vs. 67.2%, p = 0.027). No significant differences in 2-year local control rates were observed among the treatment groups (97.7% vs. 92.9% vs. 86.8%; p = 0.230). Multivariate analysis identified Proton-IO as an independent predictor of improved OS (p < 0.001), TTP (p < 0.001), and DMFS (p = 0.004). Grade 3–4 upper gastrointestinal (UGI) bleeding was observed in 2 (1.5%) patients (proton monotherapy, n = 1; Proton-IO, n = 1). There were no significant differences among the groups in the incidence of grade ≥3 UGI bleeding, liver toxicity, colitis, rib fractures, or hematologic adverse events. Conclusion: In BCLC stage B/C HCC, proton radiotherapy combined with immunotherapy was significantly associated with higher OS, TTP, and DMFS without an increase in grade ≥3 toxicity compared with proton radiotherapy alone or Proton-TKIs.Keywords
This publication has 67 references indexed in Scilit:
- Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular CarcinomaJAMA Oncology, 2025
- Proton Beam Therapy for Hepatocellular Carcinoma: Multicenter Prospective Registry Study in JapanInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: Results of a randomized clinical trialCancer, 2023
- Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Management of Hepatocellular CarcinomaJAMA Surgery, 2023
- Intensity Modulated Proton Therapy for Hepatocellular Carcinoma: Initial Clinical ExperienceAdvances in Radiation Oncology, 2021
- Predictors of Radiation-Induced Liver Disease in Eastern and Western Patients With Hepatocellular Carcinoma Undergoing Proton Beam TherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2019
- Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim AnalysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2016
- Radiation-Associated Liver InjuryInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- A Prospective Study of Hypofractionated Proton Beam Therapy for Patients With Hepatocellular CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009